Marinus Pharmaceuticals: Q4 Earnings Snapshot
Marinus Pharmaceuticals: Q3 Earnings Snapshot
Marinus Pharmaceuticals: Q2 Earnings Snapshot
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 12.99% and 94.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Marinus Pharmaceuticals: Q1 Earnings Snapshot
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 79.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H....